Glaucoma Medications - Final, not Exam 2 Flashcards
increased IOP without damage to optic nerve
Ocular hypertension
progressive optic neropathy with distinctive atrophy of the optic nerve head with cytotoxic retinal ganglion cell death, in association or not to elevated intraocular pressure
Glaucoma
Risk factors: high IOP, family hx, ethnicity, advanced age, myopia, DM, CVD
risk factors for Glaucoma
2 mechanisms for treating ocular hypertension
decrease aqueous production, increase outflow
IOP at what point requires multiple pharmacological agents?
30 mmHg
3 categories that act on the ciliary epithelium
Beta blockers, alpha 2 agonists, CAI
2 categories that affect uveoscleral outflow
prostaglandins and alpha 2 agonists
1 category affecting trabecular meshwork
direct acting cholinergics
Only category with dual action ( ciliary epithelium and uveoscleral outflow)
alpha 2 agonists
Adrenergic antagonists or sympatholytic, B2 adrenergic antagonist that block excitatory response of alpha 2 receptors responsible of aqueous humor formation
Beta blockers- timolol, lovobunolol, metipranolol, carteolol, betaxolol
B2 blocker - better iop control than pilo and eminephrine, well tolerated in CLS pts, works for 3 weeks, wash out period for 1-2 months
Timolol
Beta blocker for glaucoma with more side effects in some patients
Levobunolol
BEta blocker with no significant effect in pulmonary function for glaucoma
Betaxolol
beta blocker for glaucoma that increases HDL, less effective than levo and hydrosoluble
Carteolol
category of non bacteriostatic sulfonamides that inhbit an enzyme to reduce rate of aq humour production, found mainly in RBC, inhibits formation of bicarbonate,
CAI’s